Please enable JavaScript to continue using this application.

Compare $CAI vs $SYRE | Chartloom

Compare

$CAI vs $SYRE

Caris Life Sciences Inc · Spyre Therapeutics Inc

CAI

Caris Life Sciences Inc

SYRE

Spyre Therapeutics Inc

Compare $CAI vs $SYRE

Comparing Caris Life Sciences Inc and Spyre Therapeutics Inc

CAICaris Life Sciences Inc

SYRESpyre Therapeutics Inc

CAICaris Life Sciences Inc

Market cap

$8.40B

P/E (TTM)

79.91x

Forward P/E (NTM)

101.64x

Forward P/S (NTM)

7.48x

Rev growth (TTM)

24.4%

YTD performance

10.1%

52W performance

-9.9%

FCF yield

1.5%

SYRESpyre Therapeutics Inc

Market cap

$7.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

180.2%

52W performance

384.7%

FCF yield

-2.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CAI

SYRE

Detailed metrics comparison

CAI

Caris Life Sciences Inc

SYRE

Spyre Therapeutics Inc

Market Cap

CAI$8.40B

SYRE$7.44B

Enterprise Value

CAI$8.10B

SYRE$7.28B

Price

CAI$29.70

SYRE$85.69

P/E Ratio

CAI79.91x

SYREN/A

P/S Ratio

CAI8.48x

SYRE6,680.42x

EV/Sales

CAI8.18x

SYRE0.00x

EV/EBITDA

CAI45.95x

SYRE0.00x

P/B Ratio

CAI13.52x

SYRE7.46x

P/FCF Ratio

CAI67.73x

SYREN/A

EV/FCF

CAI65.33x

SYRE-34.84x

PEG Ratio

CAIN/A

SYREN/A

Forward P/E (NTM)

CAI101.64x

SYREN/A

Forward P/S (NTM)

CAI7.48x

SYREN/A

Revenue (TTM)

CAI$990M

SYRE$0

Revenue Growth (YoY)

CAI24.4%

SYREN/A

Forward Rev Growth

CAI18.2%

SYRE231.1%

Gross Margin (TTM)

CAI69.7%

SYRE0.0%

Operating Margin (TTM)

CAI12.7%

SYRE0.0%

EBITDA Margin (TTM)

CAI17.6%

SYRE0.0%

Net Margin (TTM)

CAI10.6%

SYRE0.0%

FCF Margin (TTM)

CAI12.5%

SYREN/A

Net Income (TTM)

CAI$105M

SYRE$-179M

FCF (TTM)

CAI$124M

SYRE$-209M

EPS (TTM)

CAI$0.37

SYRE-$2.11

ROE (TTM)

CAI18.8%

SYRE-2432.0%

ROA (TTM)

CAI9.3%

SYRE-2223.0%

ROIC (TTM)

CAI11.2%

SYRE-2432.0%

Cash

CAI$691M

SYRE$162M

Debt

CAI$393M

SYRE$0

Net Cash/Debt

CAI$298M

SYRE$162M

Current Ratio (TTM)

CAI5.53x

SYRE18.53x

Quick Ratio (TTM)

CAI4.78x

SYRE18.09x

Debt/Equity (TTM)

CAI0.66x

SYRE0.00x

Debt/Assets (TTM)

CAI0.0%

SYRE0.0%

Interest Coverage (TTM)

CAIN/A

SYREN/A

Net Debt/EBITDA (TTM)

CAI0.00x

SYRE0.00x

Beta

CAI0.40

SYRE3.19

52W Performance

CAI-9.9%

SYRE384.7%

YTD Performance

CAI10.1%

SYRE180.2%

% from 52W High

CAI-11.7%

SYRE-22.2%

% from 52W Low

CAI109.3%

SYRE385.5%

Asset Turnover (TTM)

CAI0.88x

SYRE0.01x

FCF Yield (TTM)

CAI1.5%

SYRE-2.8%

Earnings Yield (TTM)

CAI1.3%

SYRE-2.4%

Dividend Yield (TTM)

CAIN/A

SYREN/A

Rule of 40

CAI37.0

SYRE0.0

EV/GP/RG

CAI0.86

SYREN/A

Ticker research

View CAI research View SYRE research

Metric	CAI Caris Life Sciences Inc	SYRE Spyre Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$7.44B
Enterprise Value	$8.10B	$7.28B
Price	$29.70	$85.69
P/E Ratio	79.91x	N/A
P/S Ratio	8.48x	6,680.42x
EV/Sales	8.18x	0.00x
EV/EBITDA	45.95x	0.00x
P/B Ratio	13.52x	7.46x
P/FCF Ratio	67.73x	N/A
EV/FCF	65.33x	-34.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	101.64x	N/A
Forward P/S (NTM)	7.48x	N/A
Revenue & Growth
Revenue (TTM)	$990M	$0
Revenue Growth (YoY)	24.4%	N/A
Forward Rev Growth	18.2%	231.1%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	0.0%
EBITDA Margin (TTM)	17.6%	0.0%
Net Margin (TTM)	10.6%	0.0%
FCF Margin (TTM)	12.5%	N/A
Net Income (TTM)	$105M	$-179M
FCF (TTM)	$124M	$-209M
EPS (TTM)	$0.37	-$2.11
ROE (TTM)	18.8%	-2432.0%
ROA (TTM)	9.3%	-2223.0%
ROIC (TTM)	11.2%	-2432.0%
Financial Health
Cash	$691M	$162M
Debt	$393M	$0
Net Cash/Debt	$298M	$162M
Current Ratio (TTM)	5.53x	18.53x
Quick Ratio (TTM)	4.78x	18.09x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	3.19
52W Performance	-9.9%	384.7%
YTD Performance	10.1%	180.2%
% from 52W High	-11.7%	-22.2%
% from 52W Low	109.3%	385.5%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.01x
FCF Yield (TTM)	1.5%	-2.8%
Earnings Yield (TTM)	1.3%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	0.0
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View SYRE research

Valuation

P/E Ratio

CAI

79.91x

P/S Ratio

CAI

8.48x

SYRE

6,680.42x

EV/FCF

SYRE

-34.84x

CAI

65.33x

Growth & revenue

Revenue Growth TTM

CAI

24.4%

Forward Revenue Growth

SYRE

231.1%

CAI

18.2%

Profitability & performance

Gross Margin

CAI

69.7%

SYRE

0.0%

ROE

CAI

18.8%

SYRE

-2432.0%

FCF Yield %

CAI

1.5%

SYRE

-2.8%

52-Week Performance

SYRE

384.7%

CAI

-9.9%

Detailed metrics comparison

CAI

Caris Life Sciences Inc

SYRE

Spyre Therapeutics Inc

Market Cap

CAI$8.40B

SYRE$7.44B

Enterprise Value

CAI$8.10B

SYRE$7.28B

Price

CAI$29.70

SYRE$85.69

P/E Ratio

CAI79.91x

SYREN/A

P/S Ratio

CAI8.48x

SYRE6,680.42x

EV/Sales

CAI8.18x

SYRE0.00x

EV/EBITDA

CAI45.95x

SYRE0.00x

P/B Ratio

CAI13.52x

SYRE7.46x

P/FCF Ratio

CAI67.73x

SYREN/A

EV/FCF

CAI65.33x

SYRE-34.84x

PEG Ratio

CAIN/A

SYREN/A

Forward P/E (NTM)

CAI101.64x

SYREN/A

Forward P/S (NTM)

CAI7.48x

SYREN/A

Revenue (TTM)

CAI$990M

SYRE$0

Revenue Growth (YoY)

CAI24.4%

SYREN/A

Forward Rev Growth

CAI18.2%

SYRE231.1%

Gross Margin (TTM)

CAI69.7%

SYRE0.0%

Operating Margin (TTM)

CAI12.7%

SYRE0.0%

EBITDA Margin (TTM)

CAI17.6%

SYRE0.0%

Net Margin (TTM)

CAI10.6%

SYRE0.0%

FCF Margin (TTM)

CAI12.5%

SYREN/A

Net Income (TTM)

CAI$105M

SYRE$-179M

FCF (TTM)

CAI$124M

SYRE$-209M

EPS (TTM)

CAI$0.37

SYRE-$2.11

ROE (TTM)

CAI18.8%

SYRE-2432.0%

ROA (TTM)

CAI9.3%

SYRE-2223.0%

ROIC (TTM)

CAI11.2%

SYRE-2432.0%

Cash

CAI$691M

SYRE$162M

Debt

CAI$393M

SYRE$0

Net Cash/Debt

CAI$298M

SYRE$162M

Current Ratio (TTM)

CAI5.53x

SYRE18.53x

Quick Ratio (TTM)

CAI4.78x

SYRE18.09x

Debt/Equity (TTM)

CAI0.66x

SYRE0.00x

Debt/Assets (TTM)

CAI0.0%

SYRE0.0%

Interest Coverage (TTM)

CAIN/A

SYREN/A

Net Debt/EBITDA (TTM)

CAI0.00x

SYRE0.00x

Beta

CAI0.40

SYRE3.19

52W Performance

CAI-9.9%

SYRE384.7%

YTD Performance

CAI10.1%

SYRE180.2%

% from 52W High

CAI-11.7%

SYRE-22.2%

% from 52W Low

CAI109.3%

SYRE385.5%

Asset Turnover (TTM)

CAI0.88x

SYRE0.01x

FCF Yield (TTM)

CAI1.5%

SYRE-2.8%

Earnings Yield (TTM)

CAI1.3%

SYRE-2.4%

Dividend Yield (TTM)

CAIN/A

SYREN/A

Rule of 40

CAI37.0

SYRE0.0

EV/GP/RG

CAI0.86

SYREN/A

Ticker research

View CAI research View SYRE research

Metric	CAI Caris Life Sciences Inc	SYRE Spyre Therapeutics Inc
Market & Valuation
Market Cap	$8.40B	$7.44B
Enterprise Value	$8.10B	$7.28B
Price	$29.70	$85.69
P/E Ratio	79.91x	N/A
P/S Ratio	8.48x	6,680.42x
EV/Sales	8.18x	0.00x
EV/EBITDA	45.95x	0.00x
P/B Ratio	13.52x	7.46x
P/FCF Ratio	67.73x	N/A
EV/FCF	65.33x	-34.84x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	101.64x	N/A
Forward P/S (NTM)	7.48x	N/A
Revenue & Growth
Revenue (TTM)	$990M	$0
Revenue Growth (YoY)	24.4%	N/A
Forward Rev Growth	18.2%	231.1%
Profitability
Gross Margin (TTM)	69.7%	0.0%
Operating Margin (TTM)	12.7%	0.0%
EBITDA Margin (TTM)	17.6%	0.0%
Net Margin (TTM)	10.6%	0.0%
FCF Margin (TTM)	12.5%	N/A
Net Income (TTM)	$105M	$-179M
FCF (TTM)	$124M	$-209M
EPS (TTM)	$0.37	-$2.11
ROE (TTM)	18.8%	-2432.0%
ROA (TTM)	9.3%	-2223.0%
ROIC (TTM)	11.2%	-2432.0%
Financial Health
Cash	$691M	$162M
Debt	$393M	$0
Net Cash/Debt	$298M	$162M
Current Ratio (TTM)	5.53x	18.53x
Quick Ratio (TTM)	4.78x	18.09x
Debt/Equity (TTM)	0.66x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.40	3.19
52W Performance	-9.9%	384.7%
YTD Performance	10.1%	180.2%
% from 52W High	-11.7%	-22.2%
% from 52W Low	109.3%	385.5%
Efficiency & Yields
Asset Turnover (TTM)	0.88x	0.01x
FCF Yield (TTM)	1.5%	-2.8%
Earnings Yield (TTM)	1.3%	-2.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	37.0	0.0
EV/GP/RG	0.86	N/A
Ticker research	View CAI research	View SYRE research